Visualitza VHIO - Articles científics per autor "VALCARCEL, DAVID"
Ara mostrant els elements 1-5 d 5
-
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
adès, lionel; Girshova, Larisa; Doronin, Vadim; Díez Campelo, María; KAMBHAMPATI, SUMAN; VALCARCEL, DAVID (American Society of Hematology, 2022-09-13) -
Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura
Pascual, Cristina; Mingot Castellano, María Eva; Kerguelen Fuentes, Ana Esther; García-Arroba Peinado, José; Cid, Joan; Jiménez, Moraima; VALCARCEL, DAVID (American Society of Hematology, 2022-12-27) -
Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI)
Canaro Hirnyk, Mariana ; Sánchez-González, Blanca; Álvarez Román, María Teresa; Bárez-García, Abelardo; Bernardo, Angel; Mingot Castellano, María Eva; VALCARCEL, DAVID (MDPI, 2023-10-10) -
Single-cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy
Campillo-Marcos, Ignacio; Casado-Pelaez, Marta; Davalos, Veronica; Ferrer, Gerardo; Mata Garcia, Caterina; Mereu, Elisabetta; Molero , Antonieta ; VALCARCEL, DAVID (American Association for Cancer Research, 2024-02) -
Sustained response off-treatment in eltrombopag-treated adult patients with ITP who are refractory or relapsed after first-line steroids: Primary, final, and ad-hoc analyses of the Phase II TAPER trial
Cooper, Nichola; Ghanima, Waleed; Vianelli, Nicola; yavasoglu, İrfan; Melikyan, Anait; VALCARCEL, DAVID (Wiley, 2024-01)